Haemonetics (HAE) Liabilities and Shareholders Equity (2010 - 2026)

Haemonetics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $2.4 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.24% year-over-year to $2.4 billion in Q1 2026; TTM through Mar 2026 was $9.8 billion, a 2.56% decrease from a year earlier, with the FY2026 full-year figure at $2.4 billion, down 2.24% from the prior year.
• Liabilities and Shareholders Equity retreated to $2.4 billion in Q1 2026 per HAE's latest filing, from $2.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.5 billion in Q2 2024 and bottomed at $1.8 billion in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $2.2 billion (2023), against an average of $2.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 38.94% in 2022 and slipped 3.29% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.9 billion in 2022, then increased by 17.16% to $2.2 billion in 2023, then climbed by 15.04% to $2.5 billion in 2024, then decreased by 1.6% to $2.5 billion in 2025, then dropped by 3.81% to $2.4 billion in 2026.
• Per Business Quant, the three latest HAE Liabilities and Shareholders Equity figures stand at $2.4 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.4 billion (Q3 2025).